A laboratory-built sugar, only partly digested, that feeds one family of colon bacteria and makes bowel contents more acidic. Best-supported effect: better uptake of calcium and related minerals in women with low calcium intake. Other claims rest on animal work. Gas and bloating limit the dose; nothing more serious documented. Evidence thin and manufacturer-produced. (Full Review)

Protocol

Standard maintenance dose

2–6 g daily

Range at which fecal bifidobacteria rise without the dose-limiting gas seen at higher single servings

Mineral-absorption regimen

6 g twice daily

Dose of the only positive calcium trial; the highest sustained human dose documented in the literature

Best time of day

With or just after a meal

Morning and midday dosing avoids the overnight fermentation gas that follows an evening dose

Time to effect

Mineral absorption

Genuinely unknown

Mineral balance was only assessed after roughly a year, so the onset of the calcium effect is not established

Fecal bifidobacteria

1–2 weeks

Rise measurably; the shift depends on continuing substrate and drifts back toward baseline once dosing stops

Fecal ammonia

Within 4 weeks

The readout of reduced colonic putrefaction

Benefits

Medium: Enhanced intestinal absorption of calcium and other minerals

Low: Bifidogenic shift with reduced colonic putrefaction; bowel regularity, conflicted; expansion of oxalate-degrading gut bacteria; self-efficacy in depressive illness; weight gain in underweight adults

Speculative: Attenuation of colonic inflammation; mucosal and innate immune support; suppression of allergic antibody responses; reduced abdominal fat accumulation

Contraindications

Classic galactosemia

Congenital sucrase-isomaltase deficiency (untreated)

Hereditary fructose intolerance

Immunoglobulin-E-mediated cow's-milk allergy

Confirmed small-intestinal bacterial overgrowth (until eradicated)

Severe short-bowel syndrome or high-output stoma (>1,500 mL/day)

Acute severe ulcerative colitis by Truelove and Witts criteria (until controlled)

Key Interactions

Broad-spectrum antibiotics (amoxicillin, clarithromycin, ciprofloxacin)

Osmotic laxatives (lactulose, polyethylene glycol, magnesium hydroxide)

Alpha-glucosidase inhibitors (acarbose, miglitol) and metformin

Incretin-based agents (semaglutide, tirzepatide)

Other fermentable prebiotics (inulin, fructo-oligosaccharide, galacto-oligosaccharide, resistant starch)

Bifidobacterium-containing probiotics

Calcium, magnesium and vitamin D supplements

Antidiarrheals (loperamide, bismuth subsalicylate)

Magnesium- or aluminum-containing antacids (magnesium hydroxide, aluminum hydroxide)

Elimination diets and colonoscopy preparation

Risk & Side Effects

Medium: Dose-dependent colonic gas and bloating

Low: Osmotic diarrhea at high single doses; glycemic and caloric load from the digestible fraction

Speculative: Symptom provocation in irritable bowel syndrome and bacterial overgrowth; residual lactose and galactose exposure

Monitoring

Marker	Target	Why
Stool form	Types 3–4	Detects the dose ceiling
Serum calcium (albumin-corrected)	9.2–9.8 mg/dL	Confirms mineral handling stays normal while absorption rises
Serum 25-hydroxyvitamin D	40–60 ng/mL	Shows whether active calcium uptake is already efficient
Parathyroid hormone (intact)	15–35 pg/mL	Falling values suggest improved calcium supply
Red blood cell magnesium	5.0–6.5 mg/dL	Tracks the magnesium absorption effect
Fasting glucose	75–86 mg/dL	Catches glucose load from the digestible sugar fraction
HbA1c (glycated hemoglobin)	≤5.3%	Same signal averaged over months
Serum CTX (C-terminal telopeptide)	Lower half of the age- and sex-specific reference range	Bone resorption marker; the plausible downstream of better calcium absorption
Fecal calprotectin	<50 µg/g	Confirms no inflammatory reaction in bowel-disease users
24-hour urinary oxalate	<30 mg/24 h	Relevant to stone formers; the one human study found no change
Stool Bifidobacterium relative abundance	No established target — track change from the individual's own baseline	The direct readout of what the intervention is supposed to do

Cadence: Symptom and stool record weekly through titration; blood markers at 12 weeks, again at 6 months, and every 6–12 months thereafter; bone turnover markers at 12-month intervals

Qualitative Assessment

Bowel comfort: absence of distension, audible bowel sounds and urgency in the four to eight hours after a dose
Stool regularity: consistent daily or near-daily passage without straining
Flatulence burden: a rough daily count; a sustained rise marks the ceiling dose more reliably than any laboratory value
Energy and cognitive clarity: reviewed weekly, with the caveat that the only trial to measure a psychological outcome found no change
Sleep continuity: waking overnight with abdominal discomfort suggests moving the dose earlier in the day

Lactosucrose for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment